LL-37
Also known as: Cathelicidin, Cathelicidin LL-37, CAP-18 peptide, hCAP-18/LL-37, Ropocamptide
Classification
Peptide
Regulatory Status
not-established
Sources
4
Review
n/a
Overview
LL-37 exhibits antimicrobial, anti-inflammatory, immunostimulating and potential antineoplastic activities, including regulation of leukocyte chemotaxis and cytokine production and support of wound-healing processes; nonclinical work also reports pro-apoptotic tumor-suppressive activity via p53 induction in some cancer cell contexts.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
LL-37 exhibits antimicrobial, anti-inflammatory, immunostimulating and potential antineoplastic activities, including regulation of leukocyte chemotaxis and cytokine production and support of wound-healing processes; nonclinical work also reports pro-apoptotic tumor-suppressive activity via p53 induction in some cancer cell contexts.
Interactions & cautions
Drug interactions
other immunomodulatory or antimicrobial peptides — Class risk of overlapping immune stimulation or unknown peptide interactions; no specific drug-drug interaction table is established. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw